Experts from the World Health Organization (WHO) expressed “very distrust” about the data on the side effects of certain patients on the Chinese pharmaceutical company Sinopharma’s anti-covida-19 vaccine, but firmly believe that the vaccine is effective in preventing the development of diseases.
According to Reuters, documents from the World Health Organization’s Strategic Advisory Group (SAGE) show that the Sinopharma BBIBP-CorV vaccine approved in 45 countries/regions is for adults and 65 million doses have been used so far.
This document provides clinical trial data from China, Bahrain, Egypt, Jordan and the United Arab Emirates (UAE).
The World Health Organization found that the efficacy of the third phase of clinical trials after two doses was 78.1%, slightly lower than 79.3%, as previously reported in China.
The document reads: “We are very confident that two doses of BBIBP-CorV can effectively prevent the development of covida-19 in adults aged 18 to 59.”
The document added: “However, in the third phase of the study, the vaccine safety analysis for patients with comorbidities is limited to a very small number of people with health problems other than obesity.” There is a shortage of adults and is already 60 years old.
The document stated that data regarding the protection period was also lost.
A WHO expert said: “We express extremely low confidence in the quality of data related to the risk of serious consequences after one or two doses of BBIBP-CorV vaccination for people 60 years and older and patients with comorbidities.”
The SAGE analysis was performed before the WHO Technical Advisory Group decided to approve the vaccine through an emergency procedure.